<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has filed its annual disclosure to stock exchanges confirming that it does NOT qualify as a 'Large Corporate' under the SEBI circular dated November 26, 2018. This means the company falls below the prescribed thresholds (based on borrowing and/or equity listing criteria) that would require it to make mandatory quarterly disclosures. The filing was signed by the Company Secretary (Rudalf Corriea) and CFO (Tushar Mistry) and submitted to both BSE and NSE on April 17, 2025.
This is a routine compliance filing with no material impact on the stock or shareholders. It simply confirms Alivus does not meet the Large Corporate classification, meaning no additional borrowing or fundraising disclosure obligations apply to it under this SEBI framework.